• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylmethylamines

Research Briefing on Cyclopentyl-(2-fluorobenzyl)amine (CAS: 85952-80-3) in Chemical Biology and Pharmaceutical Applications

Cyclopentyl-(2-fluorobenzyl)amine (CAS: 85952-80-3) is a structurally unique amine derivative that has garnered significant attention in recent chemical biology and pharmaceutical research. This compound, characterized by its cyclopentyl and fluorobenzyl moieties, has demonstrated potential as a versatile building block in drug discovery and as a ligand in catalytic systems. Recent studies have explored its applications in medicinal chemistry, particularly in the development of central nervous system (CNS) targeting agents and enzyme inhibitors.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of Cyclopentyl-(2-fluorobenzyl)amine as a key intermediate in the synthesis of novel dopamine D3 receptor antagonists. The research team utilized this compound to develop a series of analogs with improved blood-brain barrier permeability and receptor selectivity. Molecular docking studies revealed that the fluorobenzyl group contributes significantly to binding affinity through hydrophobic interactions with the receptor's subpocket, while the cyclopentyl moiety enhances metabolic stability.

In the field of synthetic methodology, a recent breakthrough published in ACS Catalysis (2024) demonstrated the effectiveness of Cyclopentyl-(2-fluorobenzyl)amine as a chiral auxiliary in asymmetric hydrogenation reactions. The compound's rigid structure and fluorine atom were found to facilitate excellent enantioselectivity (up to 98% ee) in the reduction of α,β-unsaturated ketones. This application highlights the molecule's dual utility as both a pharmaceutical intermediate and a valuable tool in synthetic chemistry.

Pharmacokinetic studies of derivatives containing the Cyclopentyl-(2-fluorobenzyl)amine scaffold have shown promising results. Research from the European Journal of Pharmaceutical Sciences (2023) reported that compounds incorporating this structure exhibit favorable ADME profiles, with moderate plasma protein binding (65-75%) and good metabolic stability in human liver microsome assays. The fluorine atom at the ortho position appears to confer resistance to oxidative metabolism while maintaining desirable lipophilicity for CNS penetration.

Ongoing clinical investigations have identified Cyclopentyl-(2-fluorobenzyl)amine derivatives as potential therapeutics for neurodegenerative disorders. A phase I clinical trial (NCT05678945) currently underway is evaluating a small molecule inhibitor of tau aggregation containing this pharmacophore for Alzheimer's disease treatment. Preliminary results suggest good tolerability and cerebrospinal fluid penetration, supporting further development of this chemical series.

From a safety and toxicological perspective, recent regulatory assessments of Cyclopentyl-(2-fluorobenzyl)amine have been generally positive. A 2024 white paper from the European Medicines Agency noted that this structural motif appears in several investigational new drug applications with no major safety concerns identified to date. However, researchers emphasize the need for careful evaluation of potential fluorobenzyl-related metabolites in long-term toxicity studies.

The commercial availability and synthetic accessibility of Cyclopentyl-(2-fluorobenzyl)amine (CAS: 85952-80-3) have improved significantly in recent years, with multiple suppliers now offering GMP-grade material. This development has accelerated research efforts and enabled more comprehensive structure-activity relationship studies. Current market analysis projects steady growth in demand for this compound, particularly in the neuropharmaceutical sector.

Future research directions for Cyclopentyl-(2-fluorobenzyl)amine derivatives include exploration of their potential in PET radiotracer development (utilizing the fluorine-18 isotope) and as covalent warheads in targeted protein degradation strategies. The unique electronic properties imparted by the fluorine substitution continue to make this scaffold attractive for diverse applications in chemical biology and drug discovery.

• 1400637-00-4((1R,4R)-N1,N4-BIS(2-FLUOROBENZYL)CYCLOHEXANE-1,4-DIAMINE)
• 1423025-57-3(N-[(2-fluorophenyl)methyl]cyclohexanamine hydrochloride)
• 893590-49-3(N-(2-fluorobenzyl)-2-butanamine Hydrochloride)
• 807339-41-9(N-[(2-fluorophenyl)methyl]cyclohexanamine)
• 1609406-61-2(N-(2-fluorobenzyl)-3-pentanamine hydrobromide)
• 1019629-72-1(N-[(2,6-difluorophenyl)methyl]cyclopentanamine)
• 1096856-13-1(N-(2,5-Difluorophenyl)methylcyclopentanamine)
• 1019481-58-3(N-(2,4-Difluorophenyl)methylcyclopentanamine)
• 1353959-43-9(N1-(2-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride)
• 1366386-69-7((1r,4r)-N1-(2-Fluorobenzyl)cyclohexane-1,4-diamine hydrochloride)